Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: Pharmacokinetic evidence from a randomized clinical trial

Georgios Schoretsanitis; Alan Mendelowitz; Chitra Malur; Raphael J. Braga; Nina R. Schooler; Majnu John; Jose de Leon; John M. Kane; Georgios Petrides

doi:10.1016/j.schres.2020.02.008

Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: Pharmacokinetic evidence from a randomized clinical trial

Georgios Schoretsanitis, Alan Mendelowitz, Chitra Malur, Raphael J. Braga, Nina R. Schooler, Majnu John, Jose de Leon, John M. Kane, Georgios Petrides

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	309-311
Number of pages	3
Journal	Schizophrenia Research
Volume	218
DOIs	https://doi.org/10.1016/j.schres.2020.02.008
State	Published - Apr 2020

Bibliographical note

Funding Information:
Dr. Kane has been a consultant for or has received honoraria from Alkermes, Eli Lilly, EnVivo Pharmaceuticals (Forum), Forest, Genentech, H. Lundbeck, Intracellular Therapeutics, Janssen Pharmaceuticals, Johnson and Johnson, Otsuka, Reviva, Roche, Sunovion, and Teva and is a shareholder in LB Pharmaceuticals and Vanguard Research Group. Dr. Petrides has received research support from Amgen, Astra Zeneca, Corcept, Eli Lilly, Proteus, St. Jude Medical, and Sunovion, and he has served on an advisory panel for Corcept. Dr. de Leon received researcher-initiated grants from Eli Lilly (one ended in 2003 and the other, as co-investigator, ended in 2007); from Roche Molecular Systems, Inc. (ended in 2007); and, in a collaboration with Genomas, Inc., from the NIH Small Business Innovation Research program (ended in 2010). J. de Leon has been on the advisory boards of Bristol-Myers Squibb (2003/04) and AstraZeneca (2003). Roche Molecular Systems supported one of his educational presentations, which was published in a peer-reviewed journal (2005). His lectures were supported once by Sandoz (1997), twice by Lundbeck (1999 and 1999), twice by Pfizer (2001 and 2001), three times by Eli Lilly (2003, 2006, and 2006), twice by Janssen (2000 and 2006), once by Bristol-Myers Squibb (2006), and seven times by Roche Molecular Systems, Inc. (once in 2005 and six times in 2006). All other authors declare no conflicts of interest. The original study was supported by an RO1 grant from NIMH to Dr. Petrides (MH-603930). Nevertheless, the retrospective analysis performed here did not receive funds or support from any source.

Funding Information:
The original study was supported by an RO1 grant from NIMH to Dr. Petrides ( MH-603930 ).

Funding

Dr. Kane has been a consultant for or has received honoraria from Alkermes, Eli Lilly, EnVivo Pharmaceuticals (Forum), Forest, Genentech, H. Lundbeck, Intracellular Therapeutics, Janssen Pharmaceuticals, Johnson and Johnson, Otsuka, Reviva, Roche, Sunovion, and Teva and is a shareholder in LB Pharmaceuticals and Vanguard Research Group. Dr. Petrides has received research support from Amgen, Astra Zeneca, Corcept, Eli Lilly, Proteus, St. Jude Medical, and Sunovion, and he has served on an advisory panel for Corcept. Dr. de Leon received researcher-initiated grants from Eli Lilly (one ended in 2003 and the other, as co-investigator, ended in 2007); from Roche Molecular Systems, Inc. (ended in 2007); and, in a collaboration with Genomas, Inc., from the NIH Small Business Innovation Research program (ended in 2010). J. de Leon has been on the advisory boards of Bristol-Myers Squibb (2003/04) and AstraZeneca (2003). Roche Molecular Systems supported one of his educational presentations, which was published in a peer-reviewed journal (2005). His lectures were supported once by Sandoz (1997), twice by Lundbeck (1999 and 1999), twice by Pfizer (2001 and 2001), three times by Eli Lilly (2003, 2006, and 2006), twice by Janssen (2000 and 2006), once by Bristol-Myers Squibb (2006), and seven times by Roche Molecular Systems, Inc. (once in 2005 and six times in 2006). All other authors declare no conflicts of interest. The original study was supported by an RO1 grant from NIMH to Dr. Petrides (MH-603930). Nevertheless, the retrospective analysis performed here did not receive funds or support from any source. The original study was supported by an RO1 grant from NIMH to Dr. Petrides ( MH-603930 ).

Funders	Funder number
Roche Molecular Systems, Inc.
National Institutes of Health (NIH)
National Institute of Mental Health	MH-603930
Eli Lilly and Company

Keywords

Clozapine
Clozapine-resistant
ECT
Electroconvulsive therapy
Pharmacokinetics
Treatment-resistant schizophrenia

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.schres.2020.02.008

Cite this

Schoretsanitis, G., Mendelowitz, A., Malur, C., Braga, R. J., Schooler, N. R., John, M., de Leon, J., Kane, J. M., & Petrides, G. (2020). Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: Pharmacokinetic evidence from a randomized clinical trial. Schizophrenia Research, 218, 309-311. https://doi.org/10.1016/j.schres.2020.02.008

@article{53b734721c6946afa2c8680ad481a209,

title = "Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: Pharmacokinetic evidence from a randomized clinical trial",

keywords = "Clozapine, Clozapine-resistant, ECT, Electroconvulsive therapy, Pharmacokinetics, Treatment-resistant schizophrenia",

author = "Georgios Schoretsanitis and Alan Mendelowitz and Chitra Malur and Braga, {Raphael J.} and Schooler, {Nina R.} and Majnu John and {de Leon}, Jose and Kane, {John M.} and Georgios Petrides",

note = "Funding Information: Dr. Kane has been a consultant for or has received honoraria from Alkermes, Eli Lilly, EnVivo Pharmaceuticals (Forum), Forest, Genentech, H. Lundbeck, Intracellular Therapeutics, Janssen Pharmaceuticals, Johnson and Johnson, Otsuka, Reviva, Roche, Sunovion, and Teva and is a shareholder in LB Pharmaceuticals and Vanguard Research Group. Dr. Petrides has received research support from Amgen, Astra Zeneca, Corcept, Eli Lilly, Proteus, St. Jude Medical, and Sunovion, and he has served on an advisory panel for Corcept. Dr. de Leon received researcher-initiated grants from Eli Lilly (one ended in 2003 and the other, as co-investigator, ended in 2007); from Roche Molecular Systems, Inc. (ended in 2007); and, in a collaboration with Genomas, Inc., from the NIH Small Business Innovation Research program (ended in 2010). J. de Leon has been on the advisory boards of Bristol-Myers Squibb (2003/04) and AstraZeneca (2003). Roche Molecular Systems supported one of his educational presentations, which was published in a peer-reviewed journal (2005). His lectures were supported once by Sandoz (1997), twice by Lundbeck (1999 and 1999), twice by Pfizer (2001 and 2001), three times by Eli Lilly (2003, 2006, and 2006), twice by Janssen (2000 and 2006), once by Bristol-Myers Squibb (2006), and seven times by Roche Molecular Systems, Inc. (once in 2005 and six times in 2006). All other authors declare no conflicts of interest. The original study was supported by an RO1 grant from NIMH to Dr. Petrides (MH-603930). Nevertheless, the retrospective analysis performed here did not receive funds or support from any source. Funding Information: The original study was supported by an RO1 grant from NIMH to Dr. Petrides ( MH-603930 ). ",

year = "2020",

month = apr,

doi = "10.1016/j.schres.2020.02.008",

language = "English",

volume = "218",

pages = "309--311",

}

Schoretsanitis, G, Mendelowitz, A, Malur, C, Braga, RJ, Schooler, NR, John, M, de Leon, J, Kane, JM & Petrides, G 2020, 'Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: Pharmacokinetic evidence from a randomized clinical trial', Schizophrenia Research, vol. 218, pp. 309-311. https://doi.org/10.1016/j.schres.2020.02.008

TY - JOUR

T1 - Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia

T2 - Pharmacokinetic evidence from a randomized clinical trial

AU - Schoretsanitis, Georgios

AU - Mendelowitz, Alan

AU - Malur, Chitra

AU - Braga, Raphael J.

AU - Schooler, Nina R.

AU - John, Majnu

AU - de Leon, Jose

AU - Kane, John M.

AU - Petrides, Georgios

N1 - Funding Information: Dr. Kane has been a consultant for or has received honoraria from Alkermes, Eli Lilly, EnVivo Pharmaceuticals (Forum), Forest, Genentech, H. Lundbeck, Intracellular Therapeutics, Janssen Pharmaceuticals, Johnson and Johnson, Otsuka, Reviva, Roche, Sunovion, and Teva and is a shareholder in LB Pharmaceuticals and Vanguard Research Group. Dr. Petrides has received research support from Amgen, Astra Zeneca, Corcept, Eli Lilly, Proteus, St. Jude Medical, and Sunovion, and he has served on an advisory panel for Corcept. Dr. de Leon received researcher-initiated grants from Eli Lilly (one ended in 2003 and the other, as co-investigator, ended in 2007); from Roche Molecular Systems, Inc. (ended in 2007); and, in a collaboration with Genomas, Inc., from the NIH Small Business Innovation Research program (ended in 2010). J. de Leon has been on the advisory boards of Bristol-Myers Squibb (2003/04) and AstraZeneca (2003). Roche Molecular Systems supported one of his educational presentations, which was published in a peer-reviewed journal (2005). His lectures were supported once by Sandoz (1997), twice by Lundbeck (1999 and 1999), twice by Pfizer (2001 and 2001), three times by Eli Lilly (2003, 2006, and 2006), twice by Janssen (2000 and 2006), once by Bristol-Myers Squibb (2006), and seven times by Roche Molecular Systems, Inc. (once in 2005 and six times in 2006). All other authors declare no conflicts of interest. The original study was supported by an RO1 grant from NIMH to Dr. Petrides (MH-603930). Nevertheless, the retrospective analysis performed here did not receive funds or support from any source. Funding Information: The original study was supported by an RO1 grant from NIMH to Dr. Petrides ( MH-603930 ).

PY - 2020/4

Y1 - 2020/4

KW - Clozapine

KW - Clozapine-resistant

KW - ECT

KW - Electroconvulsive therapy

KW - Pharmacokinetics

KW - Treatment-resistant schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85086523701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086523701&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2020.02.008

DO - 10.1016/j.schres.2020.02.008

M3 - Letter

C2 - 32107101

AN - SCOPUS:85086523701

SN - 0920-9964

VL - 218

SP - 309

EP - 311

JO - Schizophrenia Research

JF - Schizophrenia Research

ER -

Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: Pharmacokinetic evidence from a randomized clinical trial

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this